These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 29156677)
1. Overcoming resistance to single-agent therapy for oncogenic Jain P; Silva A; Han HJ; Lang SS; Zhu Y; Boucher K; Smith TE; Vakil A; Diviney P; Choudhari N; Raman P; Busch CM; Delaney T; Yang X; Olow AK; Mueller S; Haas-Kogan D; Fox E; Storm PB; Resnick AC; Waanders AJ Oncotarget; 2017 Oct; 8(49):84697-84713. PubMed ID: 29156677 [TBL] [Abstract][Full Text] [Related]
2. CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles. Jain P; Fierst TM; Han HJ; Smith TE; Vakil A; Storm PB; Resnick AC; Waanders AJ Oncogene; 2017 Nov; 36(45):6348-6358. PubMed ID: 28806393 [TBL] [Abstract][Full Text] [Related]
3. BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas. Olow A; Mueller S; Yang X; Hashizume R; Meyerowitz J; Weiss W; Resnick AC; Waanders AJ; Stalpers LJ; Berger MS; Gupta N; James CD; Petritsch CK; Haas-Kogan DA Clin Cancer Res; 2016 Nov; 22(21):5312-5321. PubMed ID: 27217440 [TBL] [Abstract][Full Text] [Related]
4. A Cell-Based MAPK Reporter Assay Reveals Synergistic MAPK Pathway Activity Suppression by MAPK Inhibitor Combination in Usta D; Sigaud R; Buhl JL; Selt F; Marquardt V; Pauck D; Jansen J; Pusch S; Ecker J; Hielscher T; Vollmer J; Sommerkamp AC; Rubner T; Hargrave D; van Tilburg CM; Pfister SM; Jones DTW; Remke M; Brummer T; Witt O; Milde T Mol Cancer Ther; 2020 Aug; 19(8):1736-1750. PubMed ID: 32451331 [TBL] [Abstract][Full Text] [Related]
5. Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing. Selt F; Hohloch J; Hielscher T; Sahm F; Capper D; Korshunov A; Usta D; Brabetz S; Ridinger J; Ecker J; Oehme I; Gronych J; Marquardt V; Pauck D; Bächli H; Stiles CD; von Deimling A; Remke M; Schuhmann MU; Pfister SM; Brummer T; Jones DT; Witt O; Milde T Oncotarget; 2017 Feb; 8(7):11460-11479. PubMed ID: 28002790 [TBL] [Abstract][Full Text] [Related]
7. Response to trametinib treatment in progressive pediatric low-grade glioma patients. Selt F; van Tilburg CM; Bison B; Sievers P; Harting I; Ecker J; Pajtler KW; Sahm F; Bahr A; Simon M; Jones DTW; Well L; Mautner VF; Capper D; Hernáiz Driever P; Gnekow A; Pfister SM; Witt O; Milde T J Neurooncol; 2020 Sep; 149(3):499-510. PubMed ID: 33026636 [TBL] [Abstract][Full Text] [Related]
8. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade. Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033 [TBL] [Abstract][Full Text] [Related]
9. The combination of novel targeted molecular agents and radiation in the treatment of pediatric gliomas. Dasgupta T; Haas-Kogan DA Front Oncol; 2013; 3():110. PubMed ID: 23717811 [TBL] [Abstract][Full Text] [Related]
12. Diverse Stangl C; Post JB; van Roosmalen MJ; Hami N; Verlaan-Klink I; Vos HR; van Es RM; Koudijs MJ; Voest EE; Snippert HJG; Kloosterman WP Mol Cancer Res; 2020 Apr; 18(4):537-548. PubMed ID: 31911540 [TBL] [Abstract][Full Text] [Related]
13. The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models. Sigaud R; Rösch L; Gatzweiler C; Benzel J; von Soosten L; Peterziel H; Selt F; Najafi S; Ayhan S; Gerloff XF; Hofmann N; Büdenbender I; Schmitt L; Foerster KI; Burhenne J; Haefeli WE; Korshunov A; Sahm F; van Tilburg CM; Jones DTW; Pfister SM; Knoerzer D; Kreider BL; Sauter M; Pajtler KW; Zuckermann M; Oehme I; Witt O; Milde T Neuro Oncol; 2023 Mar; 25(3):566-579. PubMed ID: 35882450 [TBL] [Abstract][Full Text] [Related]
14. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. Jiang X; Zhou J; Giobbie-Hurder A; Wargo J; Hodi FS Clin Cancer Res; 2013 Feb; 19(3):598-609. PubMed ID: 23095323 [TBL] [Abstract][Full Text] [Related]
15. Dual MAPK Inhibition Triggers Pro-inflammatory Signals and Sensitizes BRAF Xing YL; Grossauer S; Park JW; Nasajpour E; Bui B; Morales D; Panovska D; Nirschl JJ; Feng ZP; Wei R; Koeck K; Thomason W; Xiu J; Harter PN; Filipski K; Mahaney K; Ji X; Mulcahy Levy JM; Grant GA; Prolo LM; Walsh KM; Lim M; Hambardzumyan D; Petritsch CK bioRxiv; 2024 Oct; ():. PubMed ID: 39416185 [TBL] [Abstract][Full Text] [Related]
16. Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. Moriceau G; Hugo W; Hong A; Shi H; Kong X; Yu CC; Koya RC; Samatar AA; Khanlou N; Braun J; Ruchalski K; Seifert H; Larkin J; Dahlman KB; Johnson DB; Algazi A; Sosman JA; Ribas A; Lo RS Cancer Cell; 2015 Feb; 27(2):240-56. PubMed ID: 25600339 [TBL] [Abstract][Full Text] [Related]
17. Future perspective of targeted treatments in pediatric low-grade glioma (pLGG): the evolution of standard-of-care and challenges of a new era. Plant-Fox AS; Tabori U Childs Nerv Syst; 2024 Oct; 40(10):3291-3299. PubMed ID: 39085626 [TBL] [Abstract][Full Text] [Related]
18. Everolimus for Children With Recurrent or Progressive Low-Grade Glioma: Results From the Phase II PNOC001 Trial. Haas-Kogan DA; Aboian MS; Minturn JE; Leary SES; Abdelbaki MS; Goldman S; Elster JD; Kraya A; Lueder MR; Ramakrishnan D; von Reppert M; Liu KX; Rokita JL; Resnick AC; Solomon DA; Phillips JJ; Prados M; Molinaro AM; Waszak SM; Mueller S J Clin Oncol; 2024 Feb; 42(4):441-451. PubMed ID: 37978951 [TBL] [Abstract][Full Text] [Related]
19. Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway. Grimaldi AM; Simeone E; Festino L; Vanella V; Palla M; Ascierto PA Discov Med; 2015 Jun; 19(107):455-61. PubMed ID: 26175403 [TBL] [Abstract][Full Text] [Related]
20. BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma. Mistry M; Zhukova N; Merico D; Rakopoulos P; Krishnatry R; Shago M; Stavropoulos J; Alon N; Pole JD; Ray PN; Navickiene V; Mangerel J; Remke M; Buczkowicz P; Ramaswamy V; Guerreiro Stucklin A; Li M; Young EJ; Zhang C; Castelo-Branco P; Bakry D; Laughlin S; Shlien A; Chan J; Ligon KL; Rutka JT; Dirks PB; Taylor MD; Greenberg M; Malkin D; Huang A; Bouffet E; Hawkins CE; Tabori U J Clin Oncol; 2015 Mar; 33(9):1015-22. PubMed ID: 25667294 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]